Article
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Antiviral therapy - 1 Jan 2013
Lalezari Jacob, Box Terry, O'Riordan William, Mehra Purvi, Nguyen Tuan, Poordad Fred, Dejesus Edwin, Kwo Paul, Godofsky Eliot, Lawrence Shannon, Dubuc-Patrick Gloria, Chen Jie, McCarville Joseph, Pietropaolo Keith, Zhou Xiao-Jian, Sullivan-Bólyai John, Mayers Douglas
Abstract excerpt
BACKGROUND: IDX184 is a liver-targeted nucleotide prodrug that selectively inhibits HCV NS5B polymerase. METHODS: This randomized, double-blind, placebo-controlled, ascending-dose study investigated the antiviral activity, safety and pharmacokinetics of IDX184 plus pegylated interferon-α2a and ribavirin (P/R) in treatment-naive patients with genotype-1 HCV. A total of 81 patients with baseline HCV RNA≥5 log10...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.